RxDoctor Payments Data

Dayna Bolton, DPM

Podiatrist · New Orleans, LANPI 1427284868

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,530 of the $8,696 with a category attached, or 63.6%. 16 manufacturers reported payments, led by Smith+Nephew at 42.1% of the total.

$8,696in general payments, 2019–2025

Across 113 payments — averaging $76.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$4K
  • Integra Lifesciences Corporation$1K
  • Stryker$1K
  • Organogenesis Inc.$736
  • Amniox Medical, Inc.$589
  • Mimedx Group, Inc.$321
  • plus $1K from 10 others
$88,092in research payments, 2019–2025

Across 7 payments — averaging $12,585 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biotissue Holdings Inc.$88K

What the payments were for

  • Travel & lodging$3,16636%
  • Food & beverage$5,53064%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,696 in reported general payments places this provider in the 85th percentile of 68 podiatrist providers in Louisiana.

See all podiatrist providers in Louisiana

Medicare billing

Part B allowed, 2024
$21,084
Medicare patients
149
Services billed
412

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ciclopirox25$3,083
Ketoconazole45$1,256
Gabapentin108$1,010
Diclofenac Sodium32$763
Ammonium Lactate28$444
Doxycycline Monohydrate13$159

Paid to pharmacies, not to this prescriber.

Other podiatrist in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →